AI制药催化商业化前景，创新药ETF国泰（517110）涨超2.4%

Core Viewpoint - The research paradigm of AI for Science (AI4S) is revolutionizing scientific research by breaking the limitations of traditional "experimental discovery" and "manual equation derivation" through advanced modeling, simulation, and prediction in quantum, atomic, and continuous medium systems [1] Group 1: AI in Pharmaceuticals - The industry outlook for AI in pharmaceuticals is positive, with expectations for commercialization by 2026 driven by deepening collaborations in small molecule drugs and explosive growth in large molecule antibody fields [1] - The large molecule sector, particularly antibodies, is anticipated to be the biggest growth highlight by 2026, as AI can efficiently explore vast protein sequence spaces to design new antibodies with better characteristics [1] Group 2: AI in Material Science - AI new materials are expected to become a key application and investment direction within AI4S, as AI accelerates material discovery and optimizes digital processes, serving as a core engine for upgrading the manufacturing industry [1] Group 3: Investment Products - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies in the fields of innovative drug research and biopharmaceuticals from the Chinese A-share market to reflect the overall performance of innovative pharmaceutical-related listed companies [1]